Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis

Clinical and Translational Oncology

Volumn 14, Issue 3, 2012, Pages 232-236

  Sonnenblick, Amir ^a   Shriki, Anat ^a   Galun, Eithan ^a   Axelrod, Jonathan H ^a   Daum, Hagit ^a   Rottenberg, Yakir ^a   Hamburger, Tamar ^a   Mali, Bela ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Breast cancer; Immunohistochemistry; Phosphorylation; STAT3; Tissue microarray

Indexed keywords

HORMONE RECEPTOR; STAT3 PROTEIN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER GRADING; CELL NUCLEUS; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROTEIN-TYROSINE KINASES; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 84860760469     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0789-z     Document Type: Article

References (21)

1. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826 (Pubitemid 40051905)
2. Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071
3. Levy DE, Lee CK (2002) What does Stat3 do? J Clin Invest 109:1143-1148 (Pubitemid 34496591)
4. Calo V, Migliavacca M, Bazan V et al (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157-168 (Pubitemid 37485244)
5. Sonnenblick A, Levy C, Razin E (2004) Interplay between MITF, PIAS3, and STAT3 in mast cells and melanocytes. Mol Cell Biol 24:10584-10592 (Pubitemid 39603118)
6. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in in?ammation and cancer. Eur J Cancer 41:2502-2512 (Pubitemid 41540626)
7. Yoshimura A (2006) Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 97:439-447 (Pubitemid 43811583)
8. Watson CJ, Miller WR (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71:840-844
9. Perou CM, Jeffrey SS, van de Rijn M et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96:9212-9217 (Pubitemid 29374734)
10. Berclaz G, Altermatt HJ, Rohrbach V et al (2001) EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 19:1155-1160
11. Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular pro?ling of tumor specimens. Nat Med 4:844-847 (Pubitemid 28331029)
12. Nechemia-Arbely Y, Barkan D, Pizov G et al (2008) IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19:1106-1115
13. Dolled-Filhart M, Camp RL, Kowalski DP et al (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9:594-600 (Pubitemid 36182589)
14. McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235 (Pubitemid 44631925)
15. Barbieri I, Pensa S, Pannellini T et al (2010) Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 70:2558-2567
16. Barbieri I, Quaglino E, Maritano D et al (2010) Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol Carcinog 49:114-120
17. Dien J, Amin HM, Chiu N et al (2006) Signal transducers and activators of transcription-3 upregulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 169:633-642 (Pubitemid 44156319)
18. Chapman RS, Lourenco PC, Tonner E et al (1999) Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13:2604-2616 (Pubitemid 29489651)
19. Sutherland KD, Vaillant F, Alexander WS et al (2006) c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO J 25:5805-5815 (Pubitemid 44967764)
20. Sarosiek KA, Malumbres R, Nechushtan H et al (2010) Novel IL-21 signaling pathway upregulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 115:570-580
21. Real PJ, Sierra A, De Juan A et al (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21:7611-7618 (Pubitemid 35398808)